Type 2 Diabetes research study to compare Icodec and IcoSema by looking at changes in A1C
Fill in your details and Sign Up today
About the Study
This study is looking for patients who are currently using long acting insulin shots with or without oral antidiabetic medications for Type 2 Diabetes. It will look at replacing the patient’s current daily long acting insulin shots with one of two potential weekly injections instead. One of the possible weekly injections is Icodec, a once weekly long acting insulin. The other possible weekly injection is IcoSema. IcoSema is a combination of Icodec and an approved weekly injection called Semaglutide.
If you qualify, you will receive study-related care and study medication or an approved medication at no charge. You may also receive compensation for travel expenses.
To take part in the study, participants should be:
- Type 2 Diabetes
- A1C 7-10%
- 18+ years old
- Currently using long-acting insulin with or without oral anti-diabetic medications